• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

How Eastside Golf aims to break down racial barriers

admin - Latest News - September 26, 2025
admin
39 views 25 secs 0 Comments



The National Golf Foundation reports that only 3% of recreational golf players in the U.S. are Black. Olajuwon Ajanaku & Earl Cooper, the co-founders of “Eastside Golf” are taking a swing at some of the racial and economic barriers in the sport. NBC News’ Marquise Francis reports.



Source link

TAGS:
PREVIOUS
Assata Shakur, Black Liberation Army figure and activist, dies at 78
NEXT
Sept. 26, 2025, 2:33 PM EDTBy Aria BendixPresident Donald Trump on Friday gave a string of unproven medical advice about Tylenol and childhood vaccines, some of which directly contradicted guidance from his administration’s own health agencies under the leadership of Robert F. Kennedy Jr.The comments, posted to Trump’s Truth Social platform, echoed his previous remarks at a Monday press briefing where he announced that the Food and Drug Administration was warning doctors not to prescribe acetaminophen — the active ingredient in Tylenol — to pregnant women, claiming it may be tied to autism in children. The bulk of scientific research has not identified such a link.Trump again said Friday on Truth Social that pregnant women should not use Tylenol “unless absolutely necessary,” adding that young children should not take Tylenol “for virtually any reason.” The FDA warning applies to pregnant women, not children, and says Tylenol can be given during pregnancy in cases of high fever, when the fever may pose a health risk to the fetus. Trump’s comments also are inconsistent with those of Vice President JD Vance, who during an interview with NewsNation on Wednesday advised pregnant women to “follow your doctor” when it comes to taking acetaminophen.Trump does not have a medical or scientific background. The responsibility for setting vaccine or drug use recommendations falls to federal health agencies, not the White House.The president’s position on vaccines has wavered over the years. At times, he has encouraged their use and touted his first administration’s developing Covid vaccines at the beginning of the pandemic. However, his decision to appoint Kennedy, a longtime anti-vaccine activist, as health secretary and his recent spreading of vaccine misinformation have raised alarms in the scientific community. At the White House event on acetaminophen last week, Trump seemed to offer his most emphatic support to date of Kennedy’s agenda, which has included commissioning a probe into the causes of autism. Trump embarked on a tangent about how children receive too many vaccines, echoing a common talking point among vaccine skeptics.“They pump so much stuff into those beautiful little babies,” he said. “It’s a disgrace.”The Department of Health and Human Services deferred comment to the White House. A White House official said Trump was amplifying the latest HHS guidance urging people to exercise caution before taking pharmaceuticals.Trump also wrote Friday that kids should get hepatitis B shots at age 12 or older, which goes against guidance from the Centers for Disease Control and Prevention. The agency says the first dose of the three-dose series should be given within 24 hours of birth because hepatitis B can be transmitted from mother to child during delivery. The CDC’s vaccine advisory panel had been considering delaying the shot until at least one month after birth — not until age 12 — but tabled the vote last week. Children can be infected at any age through contact with the bodily fluids of a person with hepatitis B. The incurable infection can lead to liver disease, cancer and death. Doctor, medical reporter fact-check Trump announcement on acetaminophen and autism14:31Trump also said Friday that the measles, mumps and rubella (MMR) vaccine should be broken up into three shots and not “mixed” — even though the shots have been combined since 1971 and aren’t made individually. And he recommended taking the “chicken p” vaccine — presumably a reference to the chickenpox vaccine — separately. Pediatricians commonly administer the chickenpox vaccine and MMR vaccine separately, though a combination shot is available to reduce the number of shots babies receive and increase the chances that kids will get all of their vaccinations. The CDC advisory committee voted last week not to recommend that combination vaccine for small children due to an increased risk of febrile seizures (seizures prompted by fevers that tend to resolve quickly). Doctors have known about the risk for years, and many public health experts viewed the committee’s decision last week as taking choice away from parents. The vote did not change the CDC’s recommended vaccine schedule: Kids should get vaccinated for measles, mumps and rubella twice — once at 12 to 15 months and again at 4 to 6 years, per the agency. Chickenpox vaccines can be given at the same doctor’s visit. Combination MMR and chickenpox vaccines can still be given to older kids, since there is no evidence of an increased risk of febrile seizure in this age group. Trump advised people on Friday to “take vaccine in five separate medical visits,” though it is unclear whether he was referring to specific shots or the childhood immunization schedule. The American Academy of Pediatrics recommends seven well-child visits (when babies typically receive their shots) in the first year of life. However, not every doctor or parent follows that schedule to the letter, and the CDC offers ranges in which childhood immunizations can be administered.Aria BendixAria Bendix is the breaking health reporter for NBC News Digital.Monica Alba and Alana Satlin contributed.
Related Post
October 12, 2025
Palestinians look to rebuild as Israelis await hostages
October 22, 2025
Government Shutdown Enters Day 22 With No End in Sight
November 7, 2025
Nov. 7, 2025, 5:55 PM ESTBy Berkeley Lovelace Jr.President Donald Trump hailed his deal to slash the price of blockbuster weight loss drugs as a game changer, promising to make Wegovy and Zepbound more affordable for millions of Americans. But major gaps in the plan could blunt its impact, drug policy experts say: Some of the drugs the administration has promised discounts on haven’t been approved yet by the Food and Drug Administration; the lower prices for people paying out of pocket only appear to apply to the lowest doses of the drugs; and the deal doesn’t expand Medicare coverage to people seeking treatment for weight loss alone.“It’s a situation where we have more questions than answers,” said Juliette Cubanski, deputy director of the Medicare policy program at KFF, a nonpartisan health policy research group. “Based on what we didn’t hear, that suggests to me that there’s a lot that the administration itself hasn’t even ironed out as of yet.”“It just feels,” she added, “a little bit too squishy right now.”U.S. President Donald Trump, joined by members of the pharmaceutical industry and administration officials, delivers remarks on lowering drug prices in the Oval Office at the White House on November 06, 2025 in Washington, DC. Andrew Harnik / Getty ImagesThe announcement marks one of the most ambitious efforts yet to tackle the high cost of weight loss drugs in the U.S. Wegovy and Zepbound carry list prices above $1,000 a month, a cost that both Republicans and Democrats have criticized as far too high, especially compared with what other countries pay. Administration officials say there’s still time to iron out details before the lower prices take effect. The lower prices that will be available through the administration’s self-pay platform, TrumpRx, aren’t expected to go live until the end of the year, and the Medicare and Medicaid changes won’t roll out until mid-2026.“I think the administration deserves credit for continuing to try to push the envelope on finding ways to lower prescription drug prices in the U.S.,” Cubanski said. She said KFF polling shows that health care costs, including prescription drugs, are a top concern for Americans.Art Caplan, the head of the division of medical ethics at NYU Grossman School of Medicine in New York City, said the deal, while ambitious, lacks crucial details.“It’s just murky as to how this will take shape, how the programs will work,” Caplan said. “You can’t really tell from what’s going on.”Unapproved drugsSeveral forms of the drugs included in the deal haven’t yet received FDA approval. That includes oral versions of the weight loss drugs — which are still under development or FDA review — and Eli Lilly’s new multidose injection pens, which haven’t been approved but the drugmaker says are the versions included in the pricing agreement.Lawrence Gostin, director of the O’Neill Institute for National and Global Health Law at Georgetown University, said that makes the administration’s promises premature, since those lower prices can’t take effect until the products are on the market. “It is reckless to negotiate pricing deals on products which the FDA have not yet approved as safe and effective,” Gostin said. “The administration is getting way out ahead of its own safety agency.”An oral version of Wegovy, from Novo Nordisk, is being reviewed by the FDA. A decision is expected in the coming weeks. A multidose version of Zepbound is under review by the FDA, Lilly said. The company hasn’t submitted its weight loss pill, orforglipron, to the agency yet. Lilly CEO David Ricks told NBC News’ Tom Llamas on “Top Story” that the FDA would review the pill quickly. “As part of the deal, they’ve agreed to give us an expedited approval,” Ricks said. Different doses, different pricesThe White House said that both the pills and the injection pens will be available for discounted prices for people who pay out of pocket. Starting doses of weight loss pills will cost $149 for a month’s supply, and the shots will cost an average of $350 for a month’s supply, the White House said. The price of the injections is expected to fall to about $250 within two years, it said.But people may end up paying more.When people start on a weight loss drug, they start with the lowest dose possible — the starting dose — to allow the body to get used to the drug. Over the course of several months, however, they increase the dose until they get to a dose that’s effective for weight loss. Wegovy comes in five doses and Zepbound comes in six, with the most weight loss seen at the highest doses. Administration officials said the starting doses of GLP-1 pills will cost $149 a month, but did not say what higher doses would be.For the injections, the exact White House language was vague: The shots will initially have a “weighted average” price of $350 a month. Lilly, however, said Zepbound will be available at the lowest dose for $299 a month, with additional doses priced up to $449. A spokesperson for Novo Nordisk didn’t say whether doses would have different prices, but said it plans to publish an update on costs “in the coming weeks.”That means patients paying through TrumpRx could end up paying far more than the administration’s advertised prices — especially if patients don’t stay on the lowest doses for long, Caplan said. Limited coverageAs part of the deal, Lilly and Novo Nordisk will charge Medicare and Medicaid $245 for a month’s supply of the shots, a move that will likely provide savings for the programs. Medicare enrollees will have their costs capped at $50 a month. Medicaid enrollees often don’t have copays.But not everyone on Medicare or Medicaid is eligible.Under the deal, Medicare will continue to cover the weight loss drugs for people who are overweight or obese and have another qualifying condition, such as heart or kidney disease. The agreement doesn’t expand coverage to people using the drugs for weight loss alone. Medicare, by law, is barred from covering weight loss drugs, Cubanski, of KFF, said.Eli Lilly CEO talks deal to cut medication prices with the Trump administration09:10The lack of expanded coverage is a significant omission, said Stacie Dusetzina, a health policy professor at Vanderbilt University in Nashville, Tennessee. Medicare is one of the largest payers in the country, and without broader coverage, millions of patients will remain priced out even as the administration touts lower costs.“You would have to change the law or go through several regulatory steps to be able to offer coverage outside of an already covered indication,” Dusetzina said. A White House spokesperson said the administration wanted to first lower prices for patients who would most benefit, such as those with risk factors associated with obesity. It’s possible the administration could eventually expand Medicare coverage through a pilot program. Ricks, the CEO of Lilly, said at a briefing Thursday that the government plans to launch one in spring 2026 that would be voluntary for Medicare plans. Still, there are issues Medicare plans would have to weigh, Dusetzina said. “The plans will have to think about how many more people might be interested in enrolling and using these drugs and how that would affect their costs,” she said. “So, again, it’s not totally clear to me how that will get operationalized and how soon Medicare beneficiaries would expect to see lower prices.”Ricks said the pilot would be “at no cost” to the plans.Dr. Shauna Levy, a specialist in obesity medicine and the medical director of the Tulane Weight Loss Center in New Orleans, said the deal is “a step in the right direction” but she worries if the administration is overstating the potential savings.“As an obesity community, I think we will remain skeptical of this deal until we see how it actually plays out,” Levy wrote in an email. Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
November 18, 2025
Uber, Joby, testing air taxis for city travel
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved